RecruitingNot Applicable

Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score

China3,000 participantsStarted 2025-11-01

Plain-language summary

The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring. This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).

Who can participate

Age range40 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients aged 40-75 years who undergo the IEE examination * patients who voluntarily sign the informed consent form Exclusion Criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy * patients with previous surgical procedures on the stomach

What they're measuring

Performance of AI system to diagnose the grade of intestinal metaplasia by calculating the EGGIM score

Timeframe: 1 year

Trial details

NCT IDNCT07257796

SponsorQilu Hospital of Shandong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-05-31

View on ClinicalTrials.gov More Intestinal Metaplasia of Gastric Mucosa trials